Balveen Kaur
Affiliations: | Neuroscience | Ohio State University, Columbus, Columbus, OH |
Area:
Neuroscience BiologyGoogle:
"Balveen Kaur"Mean distance: 53433
Parents
Sign in to add mentor| Paul W. Doetsch | grad student | (Chemistry Tree) | |
| Erwin G. Van Meir | post-doc | 1999-2005 |
Children
Sign in to add trainee| Christopher Alvarez-Breckenridge | grad student | Ohio State | |
| Chelsea Bolyard | grad student | Ohio State | |
| Jayson Hardcastle | grad student | Ohio State | |
| Hans Meisen | grad student | Ohio State | |
| Jeffrey Wojton | grad student | Ohio State | |
| Jeffrey Wojton | grad student | Ohio State | |
| Amy M. Haseley | grad student | 2012 | Ohio State |
| Ji Young Yoo | post-doc | Ohio State |
Collaborators
Sign in to add collaborator| Michael A. Caligiuri | collaborator | City of Hope (Cell Biology Tree) | |
| E. Antonio Chiocca | collaborator | ||
| Avner Friedman | collaborator | Ohio State | |
| Joseph C. Glorioso | collaborator | ||
| Maninder Khosla | collaborator | ||
| Tae Jin Lee | collaborator | UTHSC-Houston | |
| Vinay Puduvalli | collaborator | ||
| Jianhua yu | collaborator | City of Hope |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Li X, Yan X, Wang Y, et al. (2023) The Notch signaling pathway: a potential target for cancer immunotherapy. Journal of Hematology & Oncology. 16: 45 |
| Sahu U, Mullarkey MP, Pei G, et al. (2023) oHSV-P10 reduces glioma stem cell enrichment after oncolytic HSV therapy. Molecular Therapy Oncolytics. 29: 30-41 |
| Hong B, Sahu U, Mullarkey MP, et al. (2023) PKR induces TGF-β and limits oncolytic immune therapy. Journal For Immunotherapy of Cancer. 11 |
| Swanner J, Shim JS, Rivera-Caraballo KA, et al. (2023) esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation. Molecular Therapy Oncolytics. 28: 171-181 |
| Saini U, Smith BQ, Dorayappan KDP, et al. (2023) Correction: Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus. Journal of Ovarian Research. 16: 38 |
| Saini U, Smith BQ, Dorayappan KDP, et al. (2022) Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus. Journal of Ovarian Research. 15: 130 |
| Tian L, Xu B, Chen Y, et al. (2022) Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity. Nature Cancer |
| Banasavadi-Siddegowda YK, Namagiri S, Otani Y, et al. (2022) Targeting protein arginine methyltransferase 5 sensitizes glioblastoma to trametinib. Neuro-Oncology Advances. 4: vdac095 |
| Rivera-Caraballo KA, Nair M, Lee TJ, et al. (2022) The complex relationship between integrins and oncolytic herpes Simplex Virus 1 in high-grade glioma therapeutics. Molecular Therapy Oncolytics. 26: 63-75 |
| Anami Y, Otani Y, Xiong W, et al. (2022) Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors. Cell Reports. 39: 110839 |